Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
89 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Metastatic Liver Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Metastatic Liver Cancer - Pipeline Review, H2 2014', provides an overview of the Metastatic Liver Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Liver Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Liver Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Liver Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Liver Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Liver Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Liver Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Liver Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Metastatic Liver Cancer Overview 7 Therapeutics Development 8 Pipeline Products for Metastatic Liver Cancer - Overview 8 Pipeline Products for Metastatic Liver Cancer - Comparative Analysis 9 Metastatic Liver Cancer - Therapeutics under Development by Companies 10 Metastatic Liver Cancer - Therapeutics under Investigation by Universities/Institutes 12 Metastatic Liver Cancer - Pipeline Products Glance 13 Clinical Stage Products 13 Early Stage Products 14 Metastatic Liver Cancer - Products under Development by Companies 15 Metastatic Liver Cancer - Products under Investigation by Universities/Institutes 16 Metastatic Liver Cancer - Companies Involved in Therapeutics Development 17 F. Hoffmann-La Roche Ltd. 17 Celsion Corporation 18 Arrowhead Research Corporation 19 Provectus Biopharmaceuticals, Inc. 20 Transgene Biotek Limited 21 Mirna Therapeutics, Inc. 22 AB Science 23 KAEL-GemVax Co., Ltd. 24 Metastatic Liver Cancer - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 34 codrituzumab - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 tertomotide - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 masitinib - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Monoclonal Antibody Conjugate Targeting CEA for Metastatic Liver and Colorectal Cancer - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Stem Cell Therapy for Oncology - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 PV-10 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 rRp-450 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 MRX-34 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 PSL-001 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 doxorubicin liposomal - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 TBL-0404 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Peptide for Metastatic Liver Cancer - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Metastatic Liver Cancer - Recent Pipeline Updates 53 Metastatic Liver Cancer - Dormant Projects 78 Metastatic Liver Cancer - Discontinued Products 79 Metastatic Liver Cancer - Product Development Milestones 80 Featured News & Press Releases 80 Apr 09, 2014: Celsion's ThermoDox Plus High Intensity Focused Ultrasound Highlighted at 14th International Symposium on Therapeutic Ultrasound 80 Mar 06, 2014: PV-10 Immune Mechanism Data to Be Presented at the American Association for Cancer Research Annual Meeting 81 Oct 24, 2013: Provectus Awarded PV-10 Patent by U.S. Patent and Trademark Office 82 Sep 27, 2012: Provectus Pharma Expands Protocol For Phase I Liver Cancer Study 82 Aug 15, 2012: Delcath Submits New Drug Application For Chemosaturation System To FDA 83 Jun 07, 2012: Celsion To Begin Clinical Study Of ThermoDox For Metastatic Liver Cancer In Collaboration With University Of Oxford 83 Jun 05, 2012: Delcath Systems Presents Post-Hoc Analysis From Phase III Study Of Melphalan 84 Mar 02, 2010: Celsion Plans To Launch Phase II Program To Study ThermoDox In Combination With RFA For Colorectal Liver Metastases 85 Feb 26, 2010: Light Sciences Oncology Meets a Major Milestone in Aptocine Development With Target Enrollment in Phase III MCRC Trial 86 Feb 26, 2010: Light Sciences Oncology Meets a Major Milestone in Aptocine Development With Target Enrollment in Phase III MCRC Trial 86 Appendix 88 Methodology 88 Coverage 88 Secondary Research 88 Primary Research 88 Expert Panel Validation 88 Contact Us 89 Disclaimer 89
List of Tables Number of Products under Development for Metastatic Liver Cancer, H2 2014 8 Number of Products under Development for Metastatic Liver Cancer - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 11 Number of Products under Investigation by Universities/Institutes, H2 2014 12 Comparative Analysis by Clinical Stage Development, H2 2014 13 Comparative Analysis by Early Stage Development, H2 2014 14 Products under Development by Companies, H2 2014 15 Products under Investigation by Universities/Institutes, H2 2014 16 Metastatic Liver Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 17 Metastatic Liver Cancer - Pipeline by Celsion Corporation, H2 2014 18 Metastatic Liver Cancer - Pipeline by Arrowhead Research Corporation, H2 2014 19 Metastatic Liver Cancer - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2014 20 Metastatic Liver Cancer - Pipeline by Transgene Biotek Limited, H2 2014 21 Metastatic Liver Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2014 22 Metastatic Liver Cancer - Pipeline by AB Science, H2 2014 23 Metastatic Liver Cancer - Pipeline by KAEL-GemVax Co., Ltd., H2 2014 24 Assessment by Monotherapy Products, H2 2014 25 Number of Products by Stage and Target, H2 2014 27 Number of Products by Stage and Mechanism of Action, H2 2014 29 Number of Products by Stage and Route of Administration, H2 2014 31 Number of Products by Stage and Molecule Type, H2 2014 33 Metastatic Liver Cancer Therapeutics - Recent Pipeline Updates, H2 2014 53 Metastatic Liver Cancer - Dormant Projects, H2 2014 78 Metastatic Liver Cancer - Discontinued Products, H2 2014 79
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
